^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMM-101
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Immodulon
Drug class:
Dendritic cell activator
Related drugs:
Phase 2
Immodulon Therapeutics Ltd
Completed
Last update posted :
04/29/2024
Initiation :
10/04/2018
Primary completion :
12/02/2021
Completion :
12/02/2021
BRAF
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
Phase 2
AIO-Studien-gGmbH
Recruiting
Last update posted :
12/28/2023
Initiation :
12/10/2021
Primary completion :
11/15/2026
Completion :
11/15/2026
MSI
|
MSI-H/dMMR
|
Tecentriq (atezolizumab) • oxaliplatin • IMM-101
Phase 2
Immodulon Therapeutics Ltd
Completed
Last update posted :
12/02/2016
Initiation :
02/01/2012
Primary completion :
08/01/2014
Completion :
08/01/2014
CRP
|
IMM-101
Share
